Oncology

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

As patients take more proactive roles in their health, they may feel too intimidated to discuss herbal medicinal use with their providers or may be unaware of potential interactions with their drug therapies.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

Incorporating ethical principles at all levels can ensure the best possible outcomes under difficult circumstances.

Drug shortages, such as the shortages of cisplatin and carboplatin in 2023, have significantly affected oncology.

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

After allogeneic stem cell transplantation overall survival and relapse-free survival rates in patients with relapsed or refractory acute myeloid leukemia were 52% and 47%, respectively.

Imetelstat (Rytelo; Geron Corp) is a first-in-class telomerase inhibitor.

Nicolas Girard, MD, PhD, discusses the results of the PALOMA-2 trial, highlighting the subcutaneous (SC) delivery of amivantamab combined with lazertinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

Lisocabtagene maraleucel is being investigated for mantle cell lymphoma, relapsed or refractory (R/R) large B-cell lymphoma, and R/R follicular lymphoma.

Pharmacists play a crucial role in managing pain for cancer patients in palliative care.

Compared with pembrolizumab alone, the combination treatment showed stronger recurrence-free survival and distant metastasis-free survival in patients with resected high-risk stage III or IV melanoma.

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.

Asciminib demonstrated stronger efficacy, safety, and tolerability, as well as less adverse events in patients compared with those who received investigator-selected standard-of-care tyrosine kinase inhibitors.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

The phase 3 LAURA trial data presented at ASCO 2024 showed osimertinib (Tagrisso; AstraZeneca) reduced risk of disease progression or death in patients with stage 3 EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) by 84%.

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.